XORTX Therapeutics (XRTX) Depreciation & Amortization (CF) (2022 - 2026)

XORTX Therapeutics' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $22385.0 for Q1 2026.

• Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $22385.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67810.0 (up 73.55% YoY) and the FY2025 annual result came in at $85730.0, down 0.55% from the prior year.
• Depreciation & Amortization (CF) was $22385.0 for Q1 2026 at XORTX Therapeutics, down from $22537.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $22888.0 in Q3 2025 and bottomed at -$26782.6 in Q4 2023.
• A 5-year average of $13386.3 and a median of $14037.6 in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) plunged 315.93% — and 2024, when it jumped 172.86%.
• XORTX Therapeutics' Depreciation & Amortization (CF) stood at $12403.1 in 2022, then plunged by 315.93% to -$26782.6 in 2023, then soared by 172.86% to $19513.0 in 2024, then climbed by 15.5% to $22537.0 in 2025, then retreated by 0.67% to $22385.0 in 2026.
• Business Quant data shows XRTX's Depreciation & Amortization (CF) at $22385.0 in Q1 2026, $22537.0 in Q4 2025, and $22888.0 in Q3 2025.